Malignancy Risk Among Psoriasis Patients Treated With Interleukin Inhibitors: A Retrospective Matched-Cohort StudyFebruary 25, 2026Psoriasis
Psoriasis and Obesity: A Clinical Review of the Bidirectional Link and Management ImplicationsFebruary 25, 2026Psoriasis
Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque PsoriasisJanuary 13, 2026Psoriasis
Acute Generalized Exanthematous Pustulosis Secondary to Application of Tapinarof Cream 1%October 20, 2025PsoriasisMixed Topics
Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIVFebruary 5, 2025Psoriasis
The Post-PASI Era: Considering Comorbidities to Select Appropriate Systemic Psoriasis TreatmentsFebruary 3, 2025Psoriasis
Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes MellitusJanuary 3, 2025Psoriasis
